Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Nokia Corp (NOK) Price & Performance

Abbott LaboratoriesTrade
Nokia CorpTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Nokia Corp — how do they compare? Abbott Laboratories trades at $110.7 (market cap $187.95B), while Nokia Corp trades at $10.36 (market cap $53.00B). The key difference: Abbott Laboratories is far larger — about 3.5× Nokia Corp's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTNOK
Market Cap
$187.95B$53.00B
Sector
HealthTechnology
52-Week High
$136.62$16.83
52-Week Low
$82.57$4.13
Enterprise Value
$214.96B$50.95B
Dividend Yield
2.32%1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Nokia Corp

Nokia (NOK) trades at $10.375, up 13.76% today, reflecting strong momentum amid AI infrastructure demand. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, Q2 2026 earnings beat profit estimates, driven by AI and cloud growth, though revenue missed. Analyst sentiment is bullish with 60% buy ratings, while cash flow trends indicate volatility with a net outflow of $1.16B in 2025.

The outlook is cautiously optimistic, with AI-driven demand offsetting telecom challenges. Key opportunities include expanding AI networking and cloud infrastructure, but risks involve uneven telecom spending and competitive pressures. Investors should weigh strong analyst support against cash flow instability and margin pressures for balanced exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK